Mobile

A randomized, open-label, phase II maintenance study in patients with EGFR mutated, metastatic non-small-cell lung cancer who progressed after treatment with afatinib as first EGFR-targeting agent fo...

Update Il y a 4 ans
Reference: EUCTR2014-001983-36

A randomized, open-label, phase II maintenance study in patients with EGFR mutated, metastatic non-small-cell lung cancer who progressed after treatment with afatinib as first EGFR-targeting agent followed by a platinum-based induction chemotherapy Eine randomisierte, offene Phase II - Studie zur Fortführung der pan-ERBB Blockade nach einer platinbasierten Induktionschemotherapie bei Patienten mit metastasiertem, EGFR mutiertem, nicht-kleinzelligen Lungenkarzinom mit Progress nach Behandlung mit Afatinib als erste gegen den EGFR gerichtete Therapie

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic EGFR mutated non-small-cell lung cancer progressing after treatment with afatinib as first tyrosine kinase inhibitor with respect to progression-free survival

Inclusion criteria

  • Patients with stage IIIB or IV metastatic non-small-cell lung cancer with somatic EGFR mutation

Links